Evaluation of human vaccination Pfizer, Astrazeneca and Sinopharm vaccine in Iraq / Najaf

Abstract

Background: Studying the immune response to different COVID-19 vaccines is crucial for refining vaccine selection and dosage worldwide. The aim of the study is to measure the concentration IgG antibody of the human vaccinated, which include (Pfizer, AstraZeneca, and Sinopharm vaccinations) and to find out which vaccine is more efficient by RT-qPCR technology. It highlights risk factors like age and sex. The cross-sectional study took place between November 25, 2021, and January 25, 2022. Background: Studying the immune response to different COVID-19 vaccines is crucial for refining vaccine selection and dosage worldwide. The aim of the study is to measure the concentration IgG antibody of the human vaccinated, which include (Pfizer, AstraZeneca, and Sinopharm vaccinations) and to find out which vaccine is more efficient by RT-qPCR technology. It highlights risk factors like age and sex. The cross-sectional study took place between November 25, 2021, and January 25, 2022. Results: In our study of eighty-six cases, fifty tested positive for COVID-19, comprising thirty-eight females and twelve males. Monitoring occurred from the second to the seventh-month post-vaccination, with IgG titers measured via RT-qPCR. We observed higher vaccine efficacy in females compared to males. Age groups were categorized as follows: 19-29, 30-40, 41-51, and 52-62 years old. The 19-29 age group showed the highest proportion vaccinated with Pfizer, AstraZeneca, and Sinopharm vaccines. IgG concentration after 7 months was significantly higher than in earlier months. Further, IgG levels were lower in participants vaccinated with Sinopharm (p